Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, Verheul MK, Aley PK, Angus B, Bellamy D, Berrie E, Bibi S, Bittaye M, Carroll MW, Cavell B, Clutterbuck EA, Edwards N, Flaxman A, Fuskova M, Gorringe A, Hallis B, Kerridge S, Lawrie AM, Linder A, Liu X, Madhavan M, Makinson R, Mellors J, Minassian A, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy MN, Robinson H, Rollier CS, Song R, Snape MD, Tarrant R, Taylor S, Thomas KM, Voysey M, Watson MEE, Wright D, Douglas AD, Green CM, Hill AVS, Lambe T, Gilbert S, Pollard AJ; Oxford COVID Vaccine Trial Group. Barrett JR, et al. Among authors: dold c. Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. Nat Med. 2021. PMID: 33335322 Clinical Trial.
A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ. Marsay L, et al. Among authors: dold c. J Infect. 2015 Sep;71(3):326-37. doi: 10.1016/j.jinf.2015.05.006. Epub 2015 May 15. J Infect. 2015. PMID: 25982025 Free PMC article. Clinical Trial.
An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.
Norheim G, Sanders H, Mellesdal JW, Sundfør I, Chan H, Brehony C, Vipond C, Dold C, Care R, Saleem M, Maiden MC, Derrick JP, Feavers I, Pollard AJ. Norheim G, et al. Among authors: dold c. PLoS One. 2015 Sep 21;10(9):e0134353. doi: 10.1371/journal.pone.0134353. eCollection 2015. PLoS One. 2015. PMID: 26390123 Free PMC article.
Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.
Daniels-Treffandier H, de Nie K, Marsay L, Dold C, Sadarangani M, Reyes-Sandoval A, Langford PR, Wyllie D, Hill F, Pollard AJ, Rollier CS. Daniels-Treffandier H, et al. Among authors: dold c. PLoS One. 2016 Feb 12;11(2):e0148840. doi: 10.1371/journal.pone.0148840. eCollection 2016. PLoS One. 2016. PMID: 26871712 Free PMC article.
Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007.
Norheim G, Mueller JE, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ. Norheim G, et al. Among authors: dold c. Vaccine. 2018 Feb 28;36(10):1297-1303. doi: 10.1016/j.vaccine.2018.01.031. Epub 2018 Feb 2. Vaccine. 2018. PMID: 29397226 Free article.
110 results